A Correction to the Research Article Titled: “Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer” by J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner, R. K. Thomas

See allHide authors and affiliations

Science Translational Medicine  18 Apr 2012:
Vol. 4, Issue 130, pp. 130er2
DOI: 10.1126/scitranslmed.3004128

There was an error in the text, Fig. 2, and SM. The FGFR1 amplified lung cancer cell line, H520, was found during follow up experiments to be less sensitive to the FGFR inhibitor, PD173074, than initially published. Specifically, the GI50 value of this cell line is in the range of 3.9 – 6.1μM (mean value 5.1μM) leading to an error in Fig. 2A, Supplementary Table 5, and the text on page XX. However, this cell line remains one of the most FGFR inhibitor-sensitive lung cancer cell lines. As a consequence, PD173074 treatment does not induce substantial de-phosphorylation of FGFR1 or apoptosis in H520 cells causing errors in Fig. 2C and 2E. The main message of our paper, which has been confirmed by another independent report (Dutt et al., PLoS ONE 6, e20351 (2011)), remains unchanged. The corrected online version of the article is at, and the corrected PDF version of the article is at

Navigate This Article